Establishment of a Brain and Spinal Tumor Tissue Bank

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by Taipei Medical University WanFang Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT00686387
First received: May 26, 2008
Last updated: April 11, 2011
Last verified: April 2011

May 26, 2008
April 11, 2011
May 2008
May 2013   (final data collection date for primary outcome measure)
Collect, annotate, and store fresh frozen specimens of normal tissue, tumors, and pre-malignant lesions for biological investigation. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00686387 on ClinicalTrials.gov Archive Site
  • Collect, process, and store serum, plasma and isolate lymphocytes from blood drawn from patients with Brain and Spinal Tumor [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Establish a database to link materials acquisition, pathologic, and clinical information on patients who participate in the protocol [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To utilize the clinical database to perform clinical and pathological correlation with the results of current and future scientific studies [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To evaluate various NAT2, EGFR and MGMT for evidence of genomic and biochemical activation [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To test the effect of small molecule inhibitors on the activation of wild-type and mutant NAT2, EGFR, MGMT and/or other potential molecular targets [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To correlate tumor genotype and signaling abnormalities with clinical response to NAT2, EGFR, MGMT and/or other potential molecular targets inhibitors [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Analysis of laboratory findings in relationship to patient demographics and clinical course [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Establishment of a Brain and Spinal Tumor Tissue Bank
Establishment of a Brain and Spinal Tumor Tissue Bank and Clinical Data Repository for Identifying Molecular Markers of Clinical Outcome

The purpose of this study is to establish a Brain and Spinal Tumor Tissue/Specimen repository to serve as a resource for current and future scientific studies.

Glioblastoma multiforme (GBM) is the most common and lethal primary Brain and Spinal Tumor in adults. It is nearly uniformly fatal, with a median survival of approximately one year, despite modern treatment modalities. Efforts to understand why some patients live longer or shorter than the average may provide insights into the biology of these neoplasms. For years, researchers have tried to identify independent predictors that could help in treatment planning. With the recent interest in molecular biology and molecular genetics, tumor markers are now being examined as potential predictors. A marker that could predict tumor response to therapy, the likelihood of recurrence, and survival would thus be quite useful.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Whole blood, Fresh tissue

Non-Probability Sample

Neurosurgery clinic or oncology clinic in Wan Fang Hospital

  • Glioblastoma Multiforme
  • Glioma
  • Neuroectodermal Tumors
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
70
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have a suspected or confirmed diagnosis of Brain and Spinal Tumor
  • Age greater than 20
  • Signed consent

Exclusion Criteria:

  • Known HIV infection
  • Any other clinical condition which, in the opinion of the principal investigator, would not allow completion of this study
Both
20 Years and older
No
Contact: Kuo-Sheng Hung, M.D., Ph. D. 886-2-2930-7930 ext 6942 kshung25@gmail.com
Taiwan
 
NCT00686387
2008WFCRC-01
No
Kuo-Sheng Hung, MD,, Taipei Medical University-Wan Fang Hospital
Taipei Medical University WanFang Hospital
Not Provided
Principal Investigator: Kuo-Sheng Hung, MD, PhD Taipei Medical University-Wan Fang Hospital
Taipei Medical University WanFang Hospital
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP